Market Overview - U.S. stock futures declined on Thursday after a mixed close on Tuesday, with only the Nasdaq 100 index ending in positive territory [1] - The Dow Jones futures fell by 0.29%, S&P 500 by 0.23%, Nasdaq 100 by 0.30%, and Russell 2000 by 0.45% [2] - The 10-year Treasury bond yielded 4.15%, while the two-year bond was at 3.47% [2] - The CME Group's FedWatch tool indicates an 88.4% likelihood of the Federal Reserve maintaining current interest rates in January [2] Stocks in Focus - AZZ Inc. (NYSE:AZZ) shares rose by 2.8% in premarket trading after reporting strong third-quarter earnings [6] - Immuneering Corp. (NASDAQ:IMRX) shares fell by 22.93% following the announcement of updated survival and safety data from its Phase 2a trial for pancreatic cancer [6] - Northrop Grumman Corp. (NYSE:NOC) shares increased by 6.84% after President Trump proposed raising the 2027 military budget from $1 trillion to $1.5 trillion [6] - Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) shares dropped by 14.22% after announcing a $130 million public offering [14] - Constellation Brands Inc. (NYSE:STZ) shares rose by 2.32% after reporting better-than-expected third-quarter earnings [14] Economic Insights - Economist Paul Krugman warns that the Trump administration's economic policies may pose risks to the broader economy and stock market, suggesting that the market is pricing in unrealistic revenue streams [10][11] - Krugman highlights the potential disconnect between market exuberance and economic fundamentals, predicting a painful correction as the "oil fantasy" dissipates [12]

Group 1 - Phathom Pharmaceuticals, Inc. announced a public offering of 6,875,000 shares of common stock priced at $16.00 per share, along with pre-funded warrants for 1,250,078 shares priced at $15.999 each, aiming for gross proceeds of approximately $130 million before expenses [1][2] - The offering is expected to close on or about January 9, 2026, pending customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 1,218,761 shares at the public offering price [1] Group 2 - The net proceeds from the offering will be used for general corporate purposes, including working capital and expenses related to commercialization and research and development [2] - Guggenheim Securities and Cantor are acting as joint bookrunning managers, with Raymond James, Needham & Company, H.C. Wainwright & Co., and Craig-Hallum serving as co-managers for the offering [2] Group 3 - Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases, including the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker [5] - Vonoprazan is marketed in the U.S. under the brand name VOQUEZNA® for various gastrointestinal conditions, including heartburn and H. pylori infection [5]

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In additio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2026 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 100 Campus Drive, Suite 102 Florham Par ...

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.Preliminary Fourth Quarter 2025 Financial Results For the three months ended December 31, 2025, Phathom expects to report: Net revenues of approximately $57 million ...

Biotech names dominated the after-hours session on Friday, with several companies posting notable gains despite limited news catalysts.GH Research PLC (GHRS) surged the most, climbing 22.36% to $16.20, up $2.96. The sharp move came ahead of a key company update scheduled for Monday, January 5, 2026, at 7:00 a.m. EST. GH Research announced it will provide details on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA), as well as progress on ...

Based on the Phase I/II results, the FDA indicated in October that it is open to an accelerated approval pathway, including discussions around a Biologics License Application for LX2006. Pivotal data are expected in 2027, and Lexeo plans to initiate the registrational study in the first half of 2026, pending finalization of the trial protocol.The company’s leading program is LX2006, an AAV-based gene therapy designed to treat Friedreich’s ataxia cardiomyopathy by delivering a functional frataxin gene via in ...

Summary of Phathom Pharmaceuticals FY Conference Call Company Overview - **Company**: Phathom Pharmaceuticals (NasdaqGS:PHAT) - **Date of Conference**: December 02, 2025 Key Points Strategic Changes - Phathom has undergone significant changes in its operational strategy over the past year, focusing on sales calls to gastroenterologists as the primary revenue driver [5][3] - The company has reduced cash operating expenses by nearly 50%, from $360 million to $180 million, while maintaining sales force size and compensation [6][5] Sales and Marketing Strategy - The previous strategy focused heavily on primary care physicians and direct-to-consumer (DTC) advertising, which was deemed ineffective [8][9] - The current strategy emphasizes targeting gastroenterologists, who represent a more productive sector for prescriptions, as 70% of scripts come from this group [12][13] - The company has shifted away from DTC advertising, believing it does not significantly impact prescription rates [11][10] Revenue Performance - In Q3, Phathom reported approximately $50 million in revenue, with IQVIA TRX up about 17%, indicating potential for growth heading into the next quarter [15][18] - The company expects to maintain a trajectory towards profitability, with guidance suggesting positive operating profit by 2026 [33][34] Patient and Physician Engagement - The focus on gastroenterologists allows for more effective patient engagement, as these physicians treat patients who have failed previous therapies [10][27] - The company aims to create a positive feedback loop where satisfied patients advocate for the product to their primary care physicians, potentially increasing future prescriptions [28][26] Future Outlook - Phathom anticipates a revenue run rate of approximately $230 million by the end of the year, with consensus estimates for next year around $320 million, indicating a need for over 40% growth [18][19] - The company is exploring opportunities for over-the-counter (OTC) conversion of its product, which could extend market reach post-exclusivity [38][37] Financial Metrics - The company is committed to keeping expenses below $55 million for Q4, with expectations for stable operating expenses into 2026 [33][34] - Analysts suggest potential earnings power of $3-$5 per share in the future, contingent on sales growth [36][35] Additional Insights - The majority of prescriptions are for the higher 20 mg dose, indicating a focus on more severe cases of gastroesophageal reflux disease (GERD) [29][30] - The company is still in the early stages of evaluating long-term patient persistence on the medication, with initial data suggesting good refill rates [31][32] Conclusion Phathom Pharmaceuticals is strategically pivoting towards a more focused sales approach targeting gastroenterologists, which has led to significant cost reductions and a path towards profitability. The company is optimistic about future revenue growth and is exploring additional market opportunities, including OTC conversion.

Group 1 - Phathom Pharmaceutical's Voquezna and Voquezna Triple Pak are gaining market share in the U.S. GERD and H. pylori infection treatment markets [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceuticals [2] - The firm aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2]

Group 1 - Phathom Pharmaceutical's Voquezna and Voquezna Triple Pak are gaining market share in the U.S. GERD and H. pylori infection treatment markets [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceuticals [2] - The firm aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2]